Abstract

BackgroundIn 2010 EULAR/PRINTO/PRES proposed new classification criteria for IgA vasculitis (IgAV).(1) In paediatric patient population these criteria have a higher diagnostic sensitivity than the older American College of Rheumatology (ACR)...

Full Text

Published Version

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
SAT0430 Assessment of acr and slicc classification criteria in the asia pacific lupus collaboration cohort
R Kandane-Rathnayake ... M Harigai
Annals of the Rheumatic Diseases | VOL. 77
R Kandane-Rathnayake, et. al.R Kandane-Rathnayake ... M Harigai
01 Jun 2018
Brief Report: How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria.
Marta Mosca ... Sandra Navarra
Arthritis & Rheumatology | VOL. 71
Marta Mosca, et. al.Marta Mosca ... Sandra Navarra
26 Nov 2018
Prevalence and development of hip and knee osteoarthritis according to American College of Rheumatology criteria in the CHECK cohort
Jurgen Damen ... Janet Wesseling
Arthritis Research & Therapy | VOL. 21
Jurgen Damen, et. al.Jurgen Damen ... Janet Wesseling
05 Jan 2019
Fibromyalgia: Where are we a decade after the American College of Rheumatology classification criteria were developed?
Leslie J Crofford ... Daniel J Clauw
Arthritis & Rheumatism | VOL. 46
Leslie J Crofford, et. al.Leslie J Crofford ... Daniel J Clauw
01 May 2002
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults
Elizabeth M Winter ... Anne T Leerling
Annals of the Rheumatic Diseases | VOL. -
Elizabeth M Winter, et. al.Elizabeth M Winter ... Anne T Leerling
28 Nov 2024
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
Jinjing Liu ... Xiaofeng Zeng
Annals of the Rheumatic Diseases | VOL. -
Jinjing Liu, et. al.Jinjing Liu ... Xiaofeng Zeng
27 Nov 2024
CD-19 CAR-T cells for polyrefractory rheumatoid arthritis
Merav Lidar ... Abraham Avigdor
Annals of the Rheumatic Diseases | VOL. -
Merav Lidar, et. al.Merav Lidar ... Abraham Avigdor
27 Nov 2024
Correction: Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
-
Annals of the Rheumatic Diseases | VOL. -
--
27 Nov 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.